Salix Pharmaceuticals
| Type | Public (NASDAQ: SLXP) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1989 |
| Headquarters | Raleigh, North Carolina, United States |
| Key people |
Carolyn J. Logan CEO Adam C. Derbyshire CFO |
| Website | http://www.salix.com/ |
Salix Pharmaceuticals, Inc. is a specialist American pharmaceutical company. It develops drugs and medical devices that prevent and treat various gastrointestinal disorders.[1] It is listed in the Russell 2000 index. This company is listed as having the most revenue per employee (at 1,400,846) by Bizjournals.com.
History
Salix Pharmaceuticals was founded in 1989, based in Raleigh, North Carolina.
In 2003, the company survived a hostile takeover bid from Canadian pharmaceutical company Axcan Pharma Inc, now named Aptalis.[2]
Products
Approved drugs
Products marketed by Salix Pharmaceuticals include rifaximin, a rifamycin-derived antibiotic.
In development
The company is currently developing metoclopramide, a dopamine antagonist in the form of an orally disintegrating tablet (ODT).
On October 20, 2010 Salix Pharmaceuticals signed a strategic global agreement with Photocure for Lumacan. Lumacan is a photodynamic colorectal diagnostic intended to significantly improve the detection of precancerous and cancerous lesions in the colon through fluorescence diagnosis. In addition to the development of Lumacan for colorectal cancer. Salix has the exclusive right to explore and develop products for additional indications involving the diagnosis of gastrointestinal dysplasia and cancer[3]
References
- ↑ "Company Overview of Salix Pharmaceuticals Ltd". Retrieved 2012-05-03.
- ↑ Salix Pharmaceuticals Board Unanimously Recommends Rejection of Axcan's Revised Offer. Business Wire, May 27, 2003.
- ↑ http://photocure.com/Pressmedia/News/Agreement-with-Salix-Pharmaceuticals-for-Lumacan/ Photocure signs agreement with Salix Pharmaceuticals for Lumacan™